Business Wire

Landmark Study Suggests Cranberries Can Decrease Use of Antibiotics

Share

Today leading experts on infectious disease and urinary tract infections (UTIs) will gather in London to discuss the alarming state of antibiotic resistance and present findings from a landmark study that conclusively shows that cranberries can be a nutritional approach to reducing symptomatic UTIs, and as a result, may be a useful strategy to decrease worldwide use of antibiotics.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160614005444/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cue the juice– a landmark study, recently published by the American Journal of Clinical Nutrition, found that drinking an 8-ounce (240 ml) glass of cranberry juice a day reduces symptomatic UTIs by nearly 40 percent in women with recurrent UTIs– suggesting a significant reduction in the need for antibiotics. For more information, visit www.cranberryhealth.com. (Photo: Business Wire)

According to the study, recently published by the American Journal of Clinical Nutrition, drinking an 8-ounce (240 ml) glass of cranberry juice a day reduces symptomatic UTIs by nearly 40 percent in women with recurrent UTIs – reducing the burden of UTIs and reducing the antibiotic use associated with treating recurrent UTIs.

“Currently the primary approach to reducing symptomatic events of UTI is the use of chronic antibiotics for suppression, an approach associated with side effects and development of antibiotic resistance. This study shows that consuming one 8-ounce (240 ml) glass of cranberry juice a day reduces the number of times women suffer from repeat episodes of symptomatic UTI and avoids chronic suppressive antibiotics,” said Dr. Kalpana Gupta, infectious disease specialist and Professor of Medicine at Boston University’s School of Medicine.

An author on the study and panelist at today’s session, Dr. Gupta believes that cranberries can help to reduce the worldwide use of antibiotics and significantly improve the quality of life for women who suffer from recurrent UTI symptoms.

Single Largest Clinical Trial on Cranberries of its Kind

The 24-week study of 373 women, conducted by researchers at Boston University, Biofortis Innovation Services (a division of Merieux Nutrisciences) and 18 clinical sites throughout the US and France, is the largest clinical trial of its kind examining the effects of cranberry juice consumption on UTIs. This trial adds to more than 50 years of cranberry research and supports the cranberry’s ability to support urinary tract health and reduce symptomatic UTIs among chronic UTI sufferers.

Researchers set out to find whether recurrent (or repeat) UTI sufferers could be protected from repeat infections by drinking cranberry juice. Participants were all healthy women, with an average age of 40, who had experienced at least two UTIs within the past year. During the study, participants were randomly chosen to drink a daily dose of eight ounces (240 ml) of either cranberry juice or a “placebo” beverage without cranberries.

The rate of UTIs decreased significantly among the cranberry drinkers, with just 39 diagnoses during the six-month study compared with 67 in the placebo group.

Compared to some other studies, this trial had greater statistical power to detect differences than others due to its larger sample, use of incidence density to account for the tendency of clinical UTIs to cluster in time within an individual, a high average level of compliance (98%), and a comparatively large percentage of subjects in each group completing the treatment period (86%).

What’s in a Symptom?

Women with symptomatic UTIs experience all the discomforts of a UTI, such as a strong, persistent urge to urinate or a burning sensation when urinating, but may or may not test positive for a bacterial infection upon a consult with a physician. In many instances, women are treated with antibiotics for symptom relief whether bacteria is found or not. According to Gupta, the key to avoiding the situation altogether may very well lay with the cranberry.

“The key to cranberry’s benefit is consuming a glass daily to help avoid the infection altogether,” said Gupta. “Most people wait to drink cranberry juice until they have a UTI, but once the symptoms start they’ll likely need a course of antibiotics.”

The Correlation between UTIs and Antibiotic Resistance

UTIs are among the most common bacterial infections in women worldwide. Up to 60 percent of all women suffer a UTI in their lifetime,1 and up to 25 percent experience a recurrence within six months.2 Some 150 million UTIs occur annually worldwide, according to the American Urological Association, resulting in $6 billion in annual health care costs.3

Antibiotics are usually the first line of treatment for urinary tract infections, and women who have frequent UTIs may be prescribed low-dose antibiotics. Unfortunately, chronic overuse of these drugs has increased antibiotic resistance at an alarming rate globally. So much in fact, that the World Health Organization (WHO) cites a 50 percent resistance rate to one of the most widely used antibiotics to treat UTIs.4

How Cranberries Work

Luckily, cranberries contain a unique combination of compounds including Type-A PACs (or proanthocyanidins) that prevent bacteria from sticking and causing infection. In addition to PACs, new studies have revealed a new class of compounds, xyloglucan oligosaccharides, which have similar anti-bacterial properties against E. coli as PACs5. This means there are multiple, unique elements within cranberries working hard for your health.

These unique compounds can be found in a variety of products, including cranberry juice cocktail, 100% cranberry juice, light cranberry juice, dried cranberries and cranberry extract; however most of the research surrounding cranberries and UTIs has been conducted using juice.

Cranberries, a Natural Approach to Better Health

The suggestion that a nutritional approach like cranberry juice could reduce antibiotic use is welcome news given the alarming challenge it presents to public health, one that the WHO refers to as one of the greatest challenges to public health today6, and that the UK Chancellor of the Exchequer said could become a threat ‘greater than cancer’.7

According to Gupta, those who suffer from UTIs can feel confident that this nutritional approach is a potential solution – further validating more than 50 years of well-documented cranberry research.

Find more information on the study and the health benefits of cranberries at www.cranberryhealth.com.

About Cranberry Health Benefits

For more than 85 years, Ocean Spray has been actively researching the cranberry’s unique healthy benefits to deliver products that not only taste good, but are good for you. Cranberries are an exceptional fruit that provide one-of-a-kind health benefits. Besides helping consumers meet the recommended daily intake of fruit, consuming cranberries may be a nutritional approach in helping to reduce certain infections in the urinary tract and stomach. This is increasingly important as the bacteria that cause these infections are becoming highly resistant to the strongest antibiotics used to treat them, fueling what the World Health Organization believes is one of the greatest challenges to public health today – antibiotic resistance. For more information about cranberries and your health, visit www.cranberryhealth.com.

About Ocean Spray

Ocean Spray is a vibrant agricultural cooperative owned by more than 700 cranberry and grapefruit growers in the United States, Canada and Chile who have helped preserve the family farming way of life for generations. Formed in 1930, Ocean Spray is now the world’s leading producer of cranberry juices, juice drinks and dried cranberries and is the best-selling brand in the North American bottled juice category. The cooperative’s cranberries are currently featured in more than a thousand great-tasting, good-for-you products in over 100 countries worldwide. With more than 2,000 employees and nearly 20 cranberry receiving and processing facilities, Ocean Spray is committed to managing our business in a way that respects our communities, employees and the environment. For more information visit: www.oceanspray.com or www.oceanspray.coop.

1 Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000 Nov;10(8):509-15.

2 Foxman B, Brown P.Epidemiology of urinary tract infections: transmission and risk factors, incidence, and costs. Infect Dis Clin North Am. 2003 Jun;17(2):227-41.

3 American Urological Association. “Adult UTI: Epidemiology/Socioeconomics/Education.” Available at: https://www.auanet.org/education/adult-uti.cfm

4 Antimicrobial resistance: global report on surveillance 2014; WHO; http://www.who.int/drugresistance/documents/surveillancereport/en/

5 Hotchkiss AT, Nunez A, Strahan GD, Chau H, White A, Marais J, Hom K, Vakkalanka MS, Di R, Yam KL, Khoo C. Cranberry Xyloglucan Structure and Inhibition of Escherichia coli Adhesion to Epithelial Cells. J Agric Food Chem. 2015 Jun 17;63(23):5622-33.

6 Antimicrobial resistance: global report on surveillance 2014; WHO; http://www.who.int/drugresistance/documents/surveillancereport/en/

7 http://www.dailymail.co.uk/news/article-3539189/Common-infections-deadlier-threat-CANCER-unless-antibiotic-problems-tackled-George-Osborne-warns.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Weber Shandwick for Ocean Spray
Kelly Vesty, 617-520-7061
kvesty@webershandwick.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release

H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation

Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release

Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private

Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding

Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår

V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release

V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust

Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release

Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo

World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye